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Abstract
In 2015–2016, we and others reported ALDH18A1 mutations causing dominant
(SPG9A) or recessive (SPG9B) spastic paraplegia. In vitro production of the
ALDH18A1 product, D1-pyrroline-5-carboxylate synthetase (P5CS), appeared
necessary for cracking SPG9 disease-causing mechanisms. We now describe a
baculovirus–insect cell system that yields mgs of pure human P5CS and that
has proven highly valuable with two novel P5CS mutations reported here in
new SPG9B patients. We conclude that both mutations are disease-causing, that
SPG9B associates with partial P5CS deficiency and that it is clinically more sev-
ere than SPG9A, as reflected in onset age, disability, cognitive status, growth,
and dysmorphic traits.
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Introduction
ALDH18A1 gene-related spastic paraplegias (SPG9A and
SPG9B) are extremely rare disorders recognized quite
recently.1,2 They are due to mutations in ALDH18A1
(Fig. 1A), which encodes D1-pyrroline-5-carboxylate syn-
thetase (P5CS), an enzyme that catalyzes the initial two
steps of ornithine and proline biosynthesis.3,4 This bifunc-
tional single-chain homo-oligomeric2 protein is composed
of glutamate 5-kinase (G5K) and glutamyl-5-phosphate
(G5P) reductase (G5PR) components3 (Fig. 1A). Biallelic
ALDH18A1 mutations were known to cause a cutis laxa
neurocutaneous syndrome5,6 (ARCL3A, MIM#219150). In
2015–2016, we and others1,2 reported ALDH18A1 muta-
tions in dominant complicated spastic paraplegia (SPG9A,
MIM#601162). A recessive form of SPG9 (SPG9B) associ-
ated to biallelic ALDH18A1 mutations was also reported1
(SPG9B, MIM#616586). The effects of ALDH18A1-related
disease mutations appear to result from loss of P5CS7–9/de-
crease of P5CS function1,2,5,6,10–12, leading to the proposal
that dominant mutations cause ALDH18A1 pathologies by
a dominant negative effect2,11,12. Similarly to Charcot-
Marie-Tooth disease due to GDAP1 gene mutations13, it is
conceivable that dominant SPG9 mutations could cause a
less severe disease phenotype than biallelic recessive ones.
If disease severity in SPG9 has to be correlated with
P5CS enzyme activity, it is crucial to have a procedure for
directly testing the mutations’ effects on P5CS activity and
stability. We describe here this procedure for in vitro pro-
duction of pure P5CS using an engineered baculovirus–in-
sect cell system, exemplifying the value of this system with
two novel ALDH18A1 mutations found in a new family of
SPG9B that is also reported here. In addition, we rational-
ize the observed effects of these mutations using the crystal
structure (Protein Database, PDB, entry 2H5G) of the
G5PR component of human P5CS. Furthermore, by
expanding by one family the meager (just 6 prior fami-
lies)1,9,14,15 SPG9B database, we conclude on sound bases
that SPG9B is generally more severe than SPG9A.
Materials and Methods
See Supplementary Methods for details.
Production of human P5CS
An engineered baculovirus was prepared16–18 (Fig. 1B) by
co-transfection of Sf9 cells with bacmid DH10:KO1629
and with a pOPINM plasmid (Clontech) bearing the
mature human P5CS coding sequence (Fig. S1). This
virus was used for production in Sf9 insect cells of P5CS
preceded by a His6-MBP-3C protease cleavable double
tag17. Clinical mutations were introduced by site-directed
mutagenesis of the pOPINM derivative carrying the P5CS
Figure 1. Human P5CS, its “in vitro” production and assay in wild-type and mutant forms, and structure-based inferences. (A) Linear scheme of
the composition of the P5CS polypeptide, with the N-terminal mitochondrial targeting sequence in yellow, the G5K component in white and the
cofactor-binding, catalytic and oligomerization domains of the G5PR component in blue, red, and gray, respectively. The different mutations
(single letter amino acid code) reported in SPG9A (blue) and SPG9B (red), including the two mutations reported here (yellow banners) are
mapped. The two residues spliced out in the short form of P5CS, and the catalytic Cys612 of the G5PR domain are mapped and labeled in green.
The reactions catalyzed are shown below the corresponding components, and the role of the two reactions in the synthesis of proline, ornithine
(and arginine and urea) are also schematized. OAT, ornithine transcarbamylase; PYCR1, pyrrolin-5-carboxylate reductase. (B)
Diagram schematizing the production and purification of recombinant human P5CS using a baculovirus/insect cell system. Sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE, 10% polyacrylamide gel, with Coomasie staining) of the enzyme preparations produced
and used in these studies is shown. The band corresponding to P5CS, as well as to traces of residual uncleaved MBP-tagged P5CS and free MBP
tag are identified. St, protein markers, with masses given in kDa on the side. The values under the tracks give (means  SE; n of 2–4 for each
form) the yield of purified protein and the specific activities in the global P5CS reaction and the partial G5K reaction. (C) Dependency of G5PR
activity of wild type or mutant forms on the concentration of Escherichia coli G5K (top graph), added as a source of G5P, or on the
concentration of NADPH (bottom graph). (D) Thermofluor assays (means of three experiments) for purified wild type (WT) and mutant P5CS
forms. Addition of 0.2 mmol/L NADPH did not alter the thermofluor profiles of these three protein forms (data not shown). The broken line
shows the unfolding profile for isolated MBP, to show that the profiles observed with P5CS are not due to the traces of free MBP present in the
sample. Tm values are indicated with interrupted straight lines. (E) Structure of the human G5PR component of P5CS (PDB file 2H5G), mapping
therein the residues that are mutated in the present patients. Drawings are cartoon representations, with blue coloring of the cofactor-binding
domain and the b hairpin emerging from it as a part of the oligomerization domain; and with red coloring of the catalytic domain and the C-
terminal extension of this domain that ends as the two final strands of the oligomerization domain. To localize the substrate-binding sites, NADP
has been placed instead of NAD after superimposition of the NAD-bound cofactor binding domain of ALDH (PDB 1AD3) on this domain of
human G5PR. To localize the amino acid site, the a-aminoadipate of the homologous enzyme a-aminoadipate dehydrogenase has been placed on
the equivalent location of G5PR by superimposing the subunit of this enzyme in the a-aminoadipate-bound form (PDB 4ZUL) with the human
G5PR subunit structure. These ligands are shown in semitransparent spheres representation, with C, P, O and N atoms colored gray, magenta,
red, and blue, respectively. In the upper panel, a subunit is shown (residues Arg375 and Ser497 in yellow spheres, and Cys612 as a cyan sphere),
zooming in the middle panel on the hydrophobic nest around Ser497 (amino acids side-chains in sticks; broken line, a hydrogen bond), while the
bottom panel shows the dimer, illustrating the Arg371-Asp715 intersubunit salt bridge.
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cDNA. Doubly-tagged P5CS purified by tandem affinity
chromatography with MBP- and His-trap columns (GE
Healthcare) was freed from both tags by PreScission pro-
tease (GE Healthcare) digestion followed by nontagged
P5CS isolation by a final affinity chromatography step.
Enzyme activity and stability assays
Spectrophotometric activity assays at 25°C were used2,
monitoring at 340 nm the oxidation of either NADPH in
the complete P5CS reaction or the G5PR partial reaction;
Figure 2. SPG9B family tree, conservation of the mutated residues and comparison of the phenotypes of dominant and recessive forms of SPG9.
(A) The distribution of mutations (single-letter amino acid notation; WT, wild-type allele) in the family tree supports recessive inheritance. Squares,
males; circles, females. Black filling denotes a diseased individual. (B) Amino acid (single-letter code) sequence of the regions hosting the
mutations, aligned with the corresponding regions of P5CS of other species or with microbial monofunctional G5PR. Identities are highlighted in
red and conservative replacements in green. In the species names, the following abbreviations have been used: X., Xenopus; D., Drosophila; C.,
Caenorhabditis; RAPE, rapeseed; E., Escherichia; T., Thermotoga; B. THAILAND, Burkholderia thailandensis. (C) Comparison of important disease
traits in the patients reported of SPG9A1,2 or of SPG9B1,9,14,15, including those reported here. The number of patients, families, and mutations
are given on the top part. The colors from dark red to light reddish and blue reflect progressively decreasing frequencies (red hues) or not
occurrence (blue) of a given manifestation, noting in each square the frequencies (as %) with which a given clinical feature was reported in the
published patients and families of SPG9A and SPG9B. (D) Box plot summarizing the ages of disease onset for patients with SPG9A or SPG9B. The
box encompases the range between the first and the third quartile, and the whiskers define the entire range. The horizontal line within the box is
the median.
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or the oxidation of NADH in the G5K partial reaction,
coupling ADP production to NADH oxidation using
pyruvate kinase and lactate dehydrogenase.
Thermofluor assays19 were used to monitor P5CS pro-
tein unfolding with increasing temperature (1°C increase/
min). Here, Tm is the temperature giving a fluorescence
increase of 50% of the maximum increase attained.
Clinical and genetic studies
Consent was obtained for DNA sequencing, for using the
results in research, and for this publication. Retrospective
clinical and laboratory information gathered for patient
care was used, precluding the need for ethics committee
approval. We complied with the ethical principles of the
Helsinki Declaration.
Biallelic ALDH18A1 mutations were identified in the
index patient by whole-exome sequencing (WES). Sanger
sequencing (Fig. S2) was used for confirmation and for
familial segregation analysis.
Results and Discussion
See also Supplementary Results.
Production of recombinant human P5CS
We recombinantly produced human P5CS as schematized
in Figure 1B in an engineered baculovirus–insect cell sys-
tem. The doubly-tagged P5CS produced could be purified
easily by tandem affinity chromatography followed by tag
removal (PreScission protease) and a second round of
affinity purification that frees P5CS from residual non-
cleaved tagged P5CS and from the excised tags. Using this
approach, mg amounts of homogeneous largely pure
(Fig. 1B, bottom image and yield below) P5CS were
obtained from just 200 mL of insect cell culture. The MBP
tag was crucial for P5CS solubility, although tag removal
was essential for eliciting P5CS activity (data not shown).
Production of mutant forms of P5CS
The p.Arg371Gln and the p.Ser497Asn novel P5CS muta-
tions (reported here in a new SPG9B family, see below)
caused no gross P5CS misfolding, since both mutant
forms were produced and purified with similar yield as
wild-type P5CS (Fig. 1B, bottom image and yield below).
Similar success was obtained in a prior study2 with the
pilot application of this method (without describing it) to
the p.Val243Leu and p.Arg252Gln mutations found in
SPG9A families. Thus, in principle, it appears that this
procedure has general value for generating any clinical
P5CS missense mutation.
The novel SPG9B mutations p.Arg371Gln
and p.Ser497Asn decrease but do not
abolish P5CS activity
p.Arg371Gln and p.Ser497Asn did not abolish P5CS activ-
ity although both of them caused 75–80% decreases in
this activity (Fig. 1B, P5CS activity below gel image).
These decreases in activity account for disease causation.
They also show that the SPG9B phenotype is associated
with a substantial level of residual P5CS activity. In con-
trast, some patients with the ALDH18A1-caused cutis laxa
phenotype carried biallelic null mutations and exhibited
total absence of P5CS protein.7,8
In agreement with the mapping of the mutations in the
G5PR component of P5CS, these mutations did not sub-
stantially affect the G5K partial activity (Fig. 1B, G5K activ-
ity below gel image). In fact, they selectively decreased
approximately fivefold the G5PR partial activity measured
at saturation of any of the two substrates of this reaction,
G5P and NADPH (Fig. 1C, values at high concentrations of
these substrates; G5P levels are proportional to the amount
of EcG5K added, see Supplementary Methods). As Km val-
ues for these two substrates were not increased (Fig. 1C),
the decrease in the activity was purely a Vmax effect.
None of these two mutations affected importantly
P5CS thermal stability, since although they decreased Tm
values, the decrease was quite small (1–2°C, Fig. 1D).
Structure-based rationalization of the
mutations’ effects
The failure of the p.Arg371Gln and p.Ser497Asn muta-
tions to increase the Km values for G5P and NADPH in
the G5PR reaction agrees with the mapping of Arg371 or
Ser497 in the structure of the G5PR component of P5CS,
away from the inferred binding sites for these substrates
(Fig. 1E, upper panel). The magnitude of the decrease in
Vmax due to the mutations militates against a catalytic
role of Arg371 and Ser497, two residues that sit far from
the catalytic Cys612 (Fig. 1E, upper panel). It fits better
the triggering by the mutations of more indirect effects,
possibly due to changes in the equilibrium and/or the
kinetics for the opening and closing of the two globular
domains of the G5PR component inferred to take place
during catalysis.20 By making a salt bridge with Asp715 of
the other subunit of the G5PR dimer (Fig. 1E, bottom
panel), Arg371 stabilizes the open conformation. The
Arg371Gln substitution abolishes such salt bridge and
prevents this stabilization. Ser497 sits at the junction of
the cofactor-binding domain, the catalytic domain and
the oligomerization domain of the G5PR component
(Fig. 1E, upper panel). This serine makes hydrophobic
interactions in the interdomain regions that involve the
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beginning of the protruding oligomerization domain (de-
tailed in the middle panel of Fig. 1E), holding together
these elements and anchoring them on the cofactor-bind-
ing domain. Mutation to Asn could disturb this anchor-
ing, perhaps altering the dynamics rather than the
equilibrium between open and closed forms.
A novel family presenting the recessive
form of ALDH18A1-related spastic
paraplegia
We diagnosed SPG9B in a 37-year-old male (see details in
Supplementary Results) referred to us for a history of slowly
progressive gait and motor disability due to spastic paraple-
gia, which led him over many years to the use of a walker
and, from his mid-thirties, of a wheelchair. The patient
showed intellectual disability, microcephaly, short stature,
dysmorphic features (predominating facial ones), and irrita-
tive electroencephalographic findings. ALDH18A1 missense
mutations in compound heterozygosity were identified by
WES and were confirmed by Sanger sequencing (Fig. S2). A
brother of the patient showing a similar phenotype with
onset at 3 years of age, in addition presenting seizures, was
proven by Sanger sequencing to carry the same mutations as
his brother. Each parent was confirmed for one variant,
while a sister did not carry either (Fig. 2A). Family history
was negative for intellectual or motor disabilities.
The ALDH18A1 variants identified in the patients
(Table 1) were c.1112G>A and c.1490G>A. The first,
c.1112G>A, p.(Arg371Gln), affects a CpG island (hyper-
mutable islands) and was found in heterozygous state in 7
out of 282,858 alleles in the GnomAD database. The sec-
ond, c.1490G>A, p.(Ser497Asn), was unreported in data-
bases. Both mutations were absent from our local database
of WES data for nearly 1000 individuals. Neither was pre-
dicted to affect splicing (Human Splicing Finder server,
http://www.umd.be/HSF3). Pathogenicity of the variants
was supported by low or no presence of these variants in
genomic variation databases, conservation of the bases
(PhyloP scores, Table 1) and amino acids at these positions
(Fig. 2B), and by unanimous predictions of disease causa-
tion by PolyPhen2, MutPred2, and MutationTaster 2
(Table 1), and, finally, by the above-reported experimental
assays with the recombinantly produced protein.
Higher severity of SPG9B than of SPG9A
Our report of a further SPG9B family enlarges the family/
patient/mutation database (Figs. 1A and 2C), and provides
more evidence and insight into the correlation of the
SPG9A and SPG9B phenotypes with their associated geno-
types (Fig. 2C). These comparisons (Fig. 2C and D)
strongly suggest that SPG9A, caused by dominant muta-
tions, exerts less severe effects that the combined effects of
the two recessive mutations found in SPG9B patients, who
generally exhibit an earlier onset (Fig. 2D) and a progres-
sion to higher disability than SPG9A patients (Fig. 2C).
They invariably present cognitive impairment and,
Table 1. Summary of the characteristics and in silico predictions for the mutations identified in our SPG9B patients.
Nucleotide
change1
Protein
change2
Amino acid in P5CS or in
isolated microbial G5PR3
Domain of
G5PR
component
Pathogenicity server prediction
Base
conservation
Polyphen 24
MutPred25 Mutation
taster 26
PhyloP7
Animals Plants Microbial Prediction Score Score Score
c.1112G> A p.Arg371Gln R R R/k cofactor
binding
Probably damaging 1 0.623 Disease-
causing
5.035
c.1490G> A p.Ser497Asn S/t S S/t cofactor
binding
Probably damaging 1 0.791 Disease-
causing
2.746
1GeneBank (https://www.ncbi.nlm.nih.gov/nucleotide/) reference sequences for human ALDH18A1 gene, its mRNA (isoform 1, long form) and
protein (long form), NG_012258.1, NM_002860.3 and NP_002851.2, respectively. Nucleotide numbering uses + 1 as the A of the ATG translation
initiation codon (codon1).
2Uniprot KB (https://www.uniprot.org/uniprot/) reference number P54886.
3Amino acid conservation was determined by sequence alignment using Clustal, (https://www.ebi.ac.uk/Tools/msa/clustalo) of either P5CS from
animals or plants or microbial G5PR from 45, 30 or 20 species, respectively. Residues in single letter amino acid code. Non-capitalized letters
denote occurrence in low frequency.
4Polyphen-2 (HumVar-trained dataset; http://genetics.bwh.harvard.edu/pph2) grades the probability of a damaging effect of an amino acid
change, as probably damaging, possibly damaging and benign. Highest probability score is 1.
5The score given by MutPred2 (http://mutpred2.mutdb.org) is the probability that a given amino acid change is deleterious/disease associated.
6http://www.mutationtaster.org
7PhyloP measures evolutionary conservation at individual alignment sites providing positive scores at sites that are predicted to be conserved (max-
imum 6) or negative scores (mınimum 14) when sites are predicted to evolve fast. The PhyloP result was taken from the report made by Muta-
tion Taster
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frequently, short stature, microcephaly, seizures, and dys-
morphic features. These features have been reported less
frequently or not at all in SPG9A patients (Fig. 2C). Only
early cataracts seems to be more frequent in SPG9A than in
SPG9B (Fig. 2C); however, more case reports would be
needed to draw conclusions regarding cataract frequency.
Conclusions
The in vitro P5CS production system reported here is a
highly useful tool to clarify the effects of individual P5CS
mutations and thus to establish the molecular mecha-
nisms of disease causation in ALDH18A1-related disor-
ders. The use of this system has shown that the novel
P5CS mutations p.Arg371Gln and p.Ser497Asn reported
here in a new SPG9B family are disease causing, impor-
tantly decreasing P5CS enzyme activity. However, since
they do not completely inactivate this enzyme, SPG9B is
associated to partial rather than total P5CS deficiency.
With the increased SPG9B family/patient database after
addition of this new family, the dominant and recessive
form of SPG9 can be compared on sound bases, leading
to the conclusion that SPG9B is more severe than SPG9A,
having a lower onset age, attaining greater disability, pre-
senting constant impairment of cognition and more fre-
quent growth restriction and dysmorphic traits.
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Figure S1. Scheme of pOPINM-P5CS.
Figure S2. Validation of the two novel ALDH18A1 muta-
tions through Sanger sequencing in one of the two
patients.
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